Group 1 - China Medical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan to enhance its R&D capabilities in the pharmaceutical sector [1] - Hongchang Electronics has commenced production of its functional high-end copper-clad laminate electronic materials project [2] - China State Construction has secured multiple major projects totaling 32.09 billion yuan, which represents 1.5% of its audited revenue for 2024 [3] Group 2 - China Resources Double Crane has established an industrial fund with a committed investment of 83 million yuan, targeting a total fundraising goal of 500 million yuan [4] - Pinggao Electric and its subsidiaries have won state grid procurement projects worth approximately 876 million yuan, accounting for 7.06% of its 2024 revenue [5] - Dong'an Power received a government subsidy of 2.47 million yuan, with 1.47 million yuan related to assets and 1 million yuan related to income [6] Group 3 - Nantian Information has paid overdue taxes and penalties totaling 50.31 million yuan, which will impact its net profit for 2025 [7] - Erli Six has changed its investment plan to establish a wholly-owned subsidiary in Hong Kong for submarine cable business with an investment of 320 million yuan [8] - Dream Lily plans to invest 170 million yuan in an e-commerce warehouse project at its East US factory [9] Group 4 - Shen Shen Fang A's controlling shareholder has terminated the agreement to transfer 7.07% of the company's shares to Dongfang Asset, with no change in control [10] - Tianfu Culture has signed strategic cooperation framework agreements with various cultural and tourism bureaus to promote film and tourism integration [11] - Jinzi Tianzheng's chairman has resigned due to work adjustments, but will continue to fulfill his duties until a new chairman is elected [12] Group 5 - Jiangshan Oupai and its subsidiaries received government subsidies totaling 10.04 million yuan, with 7.51 million yuan related to income [13] - Ninghu Expressway plans to increase its investment in Jiangsu Danjin Expressway Co., Ltd. by 128 million yuan to support highway construction [14] - Jiangyin Bank has received approval for the qualifications of its employee director and vice president [15] Group 6 - Aoxiang Pharmaceutical has received approval for the listing application of two chemical raw materials [16] - Daye Co. has not yet commenced mass production of its robotic tendon products, with ongoing uncertainties in technology and profitability [17] - Rongsheng Environmental has proposed a cash dividend of 3.8 yuan per 10 shares, totaling approximately 97.36 million yuan [19] Group 7 - Yunyi Electric plans to invest 66 million USD in Morocco to establish a wholly-owned subsidiary and production base [20] - Derun Electronics has reached an agreement regarding the delayed payment of 100 million yuan in equity transfer funds [21] - Baihua Pharmaceutical is planning a change in control, leading to a continued suspension of its stock [22] Group 8 - CITIC Bank's executive director and president has resigned due to work adjustments [23] - Haizike's subsidiary has received acceptance for clinical trial applications for two innovative drugs [24] - Tianrun Dairy's subsidiaries received government subsidies totaling 21.53 million yuan, representing 49.32% of its net profit for 2024 [25] Group 9 - Andisou plans to issue 398 million A-shares at 7.54 yuan per share, raising a total of 3 billion yuan [26][27] - Fuda Co. has completed the transfer of its 50% stake in a joint venture, which is expected to positively impact its 2025 financial results [28] - Jianghua Micro has received environmental approval for a project to produce 37,000 tons of ultra-pure wet electronic chemicals [29] Group 10 - Nanwang Technology received a government subsidy of 10 million yuan, accounting for 0.66% of its net assets for 2024 [30] - Changgao Electric New has won state grid procurement projects totaling 161 million yuan, representing 9.14% of its 2024 revenue [31] - Huaxin Precision plans to invest up to 600 million yuan of idle funds in low-risk financial products [32] Group 11 - Fuguang Co. received a government subsidy of 1.26 million yuan for basic research projects, which is 13.27% of its net profit for 2024 [33] - Benli Technology has obtained a drug production license, which will help optimize its product structure [34] - Jintuo Co. proposed a cash dividend of 4.1 yuan per 10 shares, totaling approximately 99.48 million yuan [35] Group 12 - Kang Enbei has elected a new chairman and vice chairman during its board meeting [36] - Sanyuan Bio has completed the construction and installation of equipment for the remaining capacity of its 20,000-ton alulose project [38]

格隆汇12月30日丨本立科技(301065.SZ)公布，近日取得了由浙江省药品监督管理局颁发的《药品生产 许可证》，本次系公司首次取得《药品生产许可证》，有利于优化公司产品结构，对公司长远发展有着 积极的推动作用。公司尚须通过注册申报、现场核查等监管程序并取得原料药备案证明后，方可上市进 行商业化生产销售。《药品生产许可证》的获得短期内不会对公司经营业绩产生重大影响。 ...

本立科技公告，公司于近日取得了由浙江省药品监督管理局颁发的《药品生产许可证》。该许可证有效 期至2030年12月29日，生产地址为浙江省临海头门港新区东海第六大道15号，生产范围为原料药***。 本次取得《药品生产许可证》有利于优化公司产品结构，对公司长远发展有着积极的推动作用。 ...

关于公司取得《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江本立科技股份有限公司（以下简称"公司"）于近日取得了 由浙江省药品监督管理局颁发的《药品生产许可证》，现将相关信息 公告如下： 一、《药品生产许可证》的基本信息 企业名称：浙江本立科技股份有限公司 社会信用代码：913310005753258189 证券代码：301065 证券简称：本立科技 公告编号：2025-047 浙江本立科技股份有限公司 许可证编号：浙20250019 分类码：Dh 日常监督管理机构：浙江省药品监督管理局 注册地址：浙江省临海头门港新区东海第六大道15号 法定代表人：吴政杰 企业负责人：吴政杰 质量负责人：罗臣 有效期至：2030年12月29日 生产地址和生产范围：浙江省临海头门港新区东海第六大道15号： 原料药*** 二、对公司的影响及风险提示 本次系公司首次取得《药品生产许可证》，有利于优化公司产 品结构，对公司长远发展有着积极的推动作用。公司尚须通过注册 申报、现场核查等监管程序并取得原料药备案证明后，方可上市进 行商业化生产销售。《药品生产 ...

分红方面，本立科技A股上市后累计派现6629.18万元。近三年，累计派现4155.38万元。 机构持仓方面，截止2025年9月30日，本立科技十大流通股东中，诺安多策略混合A（320016）位居第 七大流通股东，持股70.00万股，为新进股东。 责任编辑：小浪快报 融券方面，本立科技12月23日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量6800.00股，融券余额14.37万元，超过近一年90%分位水平，处于高位。 资料显示，浙江本立科技股份有限公司位于浙江省临海头门港新区东海第六大道15号，成立日期2011年 5月13日，上市日期2021年9月14日，公司主营业务涉及医药中间体、农药中间体、新材料中间体的研 发、生产和销售。主营业务收入构成为：1501产品40.35%，1701产品16.62%，其他16.54%，801产品 14.61%，1201产品11.89%。 截至12月19日，本立科技股东户数1.03万，较上期增加0.44%；人均流通股8398股，较上期减少0.44%。 2025年1月-9月，本立科技实现营业收入4.81亿元，同比减少10.67%；归母净 ...

证券日报网讯12月22日，本立科技（301065）在互动平台回答投资者提问时表示，截至2025年12月19 日，公司股东总人数为10274户。 ...

本立科技公开发行新股的发行费用合计6814.48万元，其中长城证券股份有限公司获得保荐、承销 费用（不含增值税）4724.91万元。 2023年6月8日，本立科技发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以 公司现有总股本70,680,000股为基数，向全体股东每10股派1.500000元人民币现金，同时，以资本公积 金向全体股东每10股转增5.000000股。本次权益分派股权登记日为2023年6月15日，除权除息日为2023 年6月16日。 (责任编辑：何潇) 本立科技于2021年9月14日在深交所创业板上市，发行股票数量为1768万股，占发行后总股本的比 例为25.01%，发行价格为42.50元/股，保荐机构为长城证券股份有限公司，保荐代表人为刘逢敏、郑益 甫。上市首日，本立科技盘中创下股价高点112.99元。该股股价目前处于破发状态。 本立科技募集资金总额为7.51亿元，扣除发行费用后，募集资金净额为6.83亿元。本立科技最终募 集资金净额比原计划多2.07亿元。本立科技2021年8月31日披露的招股说明书显示，公司拟募集资金4.76 亿元，计划分别用于"基于一氧化碳羰基化反 ...

中国经济网北京12月10日讯本立科技（301065）(30106.SZ5)昨晚披露关于高级管理人员减持股份预披 露公告称，公司副总经理盛孟均直接持有本立科技股份300,000股(占公司总股本的0.28%，占剔除公司 回购专用证券账户股份数量后总股本的比例为0.29%)，通过台州少思投资合伙企业(有限合伙)(原名称为 杭州少思投资合伙企业(有限合伙)，于2025年8月25日更名)间接持有公司股份262,500股(占公司总股本 的0.25%，占剔除公司回购专用证券账户股份数量后总股本的比例为0.25%)。 盛孟均拟在公告披露之日起15个交易日后的3个月内以集中竞价交易方式减持其直接持有的公司股份不 超过75,000股，占公司总股本的0.07%，占剔除公司回购专用证券账户股份数量后总股本的比例为 0.07%。 本立科技表示，盛孟均不属于公司控股股东、实际控制人，本次股份减持计划系股东的正常减持行为， 不会对公司治理结构、股权结构及未来持续经营产生重大影响，也不会导致公司控制权发生变更。 2023年6月8日，本立科技发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以公司 现有总股本70,680, ...

Summary of Key Points Core Viewpoint - On December 9, several A-share listed companies disclosed their shareholding changes, with notable increases in shareholdings from companies like Financial Street, Songcheng Performance, and others, while 14 companies, including Shengyi Technology and Shen Zhou Information, reported reductions in shareholdings [1][2][3] Group 1: Shareholding Increases - Financial Street reported that Harmony Health Insurance increased its shareholding by 7.0384 million shares from December 4 to December 8 [2][3] - Songcheng Performance plans to repurchase shares worth between 100 million to 200 million yuan for cancellation and reduction of registered capital [2][3] - Yingpais intends to increase its shareholding by 60 million to 120 million yuan [2][3] - Huatai Medical plans to repurchase shares worth between 200 million to 250 million yuan [2][3] - American Shares plans to repurchase shares worth between 30 million to 60 million yuan [2][3] Group 2: Shareholding Reductions - Shengyi Technology's largest shareholder, Guangxin Group, reduced its holdings by 12.91 million shares from November 26 to December 9 [2][3] - Saiwei Microelectronics' shareholder, Shanghai Lingguan, plans to reduce holdings by no more than 14,500 shares [2][3] - Shen Zhou Information's controlling shareholder, Shenma Software, plans to reduce its holdings by no more than 2.95% [2][3] - Demingli's shareholder, Wei Hongzhang, reduced holdings by a total of 2.8433 million shares from November 7 to December 8 [2][3] - Ying Shisheng's controlling shareholder, Tang Qiu, reduced holdings by 1% [2][3] - Meixin Technology's shareholder, Runke Investment, plans to reduce holdings by no more than 1.6047% [2][3] - Benli Technology's deputy general manager, Sheng Mengjun, plans to reduce holdings by no more than 0.07% [2][3] - Donghua Testing's controlling shareholder and its concerted actions plan to reduce holdings by no more than 1.99% [2][3] - Kute Intelligent's controlling shareholder's concerted action, Zhang Yunlan, plans to reduce holdings by no more than 2% [2][3] - Haomei New Materials' shareholder, Chi Yao Investment, plans to reduce holdings by no more than 0.44% [2][3] - Aokang International's shareholder, Xiang Jinyu, plans to reduce holdings by no more than 3% [2][3] - Aerospace Development's fourth largest shareholder, Aerospace Science and Industry Asset Company, reduced holdings by 1.3435 million shares on December 9 [2][3] - Lide New Energy's shareholder, Shandong Electric Construction, plans to reduce holdings by no more than 1% [2][3] - Yingfang Micro's shareholding by Dongfang Securities has fallen below 5% [2][3]

每经AI快讯，本立科技（SZ 301065，收盘价：22.06元）12月9日晚间发布公告称，公司副总经理盛孟 均先生直接持有浙江本立科技股份有限公司股份30万股（占公司总股本的0.28%，占剔除公司回购专用 证券账户股份数量后总股本的比例为0.29%），通过台州少思投资合伙企业（有限合伙）（原名称为杭 州少思投资合伙企业（有限合伙），于2025年8月25日更名）间接持有公司股份约26万股（占公司总股 本的0.25%，占剔除公司回购专用证券账户股份数量后总股本的比例为0.25%）；盛孟均先生拟在本公 告披露之日起15个交易日后的3个月内以集中竞价交易方式减持其直接持有的公司股份不超过约7.5万 股，占公司总股本的0.07%，占剔除公司回购专用证券账户股份数量后总股本的比例为0.07%。 2024年1至12月份，本立科技的营业收入构成为：医药中间体占比92.78%，农药中间体占比4.15%，其 他业务占比3.07%。 截至发稿，本立科技市值为23亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王瀚黎 ...